[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yunfeng Xia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100608280","phase-2-a-self-controlled-study-on-the-treatment-of-restless-legs-syndrome-in-uremia-with-dipyridamole-100608280",false,"NCT07199504","A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole","Inclusion Criteria:\n\n(1) Maintenance hemodialysis for ≥3 months;(2) Age between 18-75 years;(3) Diagnosed with Restless Legs Syndrome (RLS) according to IRLSSG standards with a score \\>15;(4) Willing to cooperate with this study.\n\nExclusion Criteria:\n\n(1). Patients with other cerebrovascular, muscular, and movement system diseases affecting the assessment of RLS;(2). Patients with active bleeding, such as gastrointestinal bleeding or intracerebral hemorrhage;(3). Patients who have been on dipyridamole for a long time;(4). Patients who have taken other medications that may affect RLS in the last 3 weeks, such as dopamine agonists\u002Fantagonists, tricyclic antidepressants, lithium, etc.;(5). Patients with a history of psychosis;(6). Pregnant or breastfeeding women;(7). Patients who are allergic or intolerant to dipyridamole;(8). Patients who cannot or are unwilling to cooperate with this study.","ALL","18 Years","75 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The purpose of this clinical trial is to determine whether dipyridamole can treat restless legs syndrome in patients with uremia. In addition, the safety of dipyridamole will also be evaluated. The main questions this study aims to answer include: Can dipyridamole improve the symptoms of restless legs syndrome in participants? Can dipyridamole improve participants' anxiety, depression, sleep quality, and quality of life? What adverse reactions might participants experience while taking dipyridamole? This study is a self-controlled trial in which all participants receive active drug treatment. Participants will take dipyridamole daily (50 mg per dose, three times a day) for 12 weeks. The efficacy of dipyridamole will be evaluated by comparing relevant scale scores and laboratory indicators before and after treatment. In addition, adverse reactions during the treatment follow-up will be monitored to assess the safety of dipyridamole in this patient population.",[27],"Restless Leg Syndrome Due to Uraemia",[29,30],"Restless Leg Syndrome","Uraemia","RECRUITING","2026-04-18",{"date":34,"type":35},"2026-04-22","ACTUAL",{"date":37,"type":35},"2025-09-20",{"date":39,"type":20},"2026-12-31",{"name":41,"class":42},"Yunfeng Xia","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":64,"locationsCount":43},"100615326","impact-of-app-assisted-patient-management-on-the-quality-control-of-blood-purification-therapy-100615326","NCT07291154","Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy","Inclusion Criteria:\n\n* Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.\n* Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.\n* Patients who can understand and proficiently use WeChat and the \"Yueya\" mini - program used in this study.\n\nExclusion Criteria:\n\n* Patients with communication barriers or other conditions that prevent them from cooperating with the study.\n* Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.\n* Patients who are not willing to actively cooperate with the study.\n* Patients with severe liver cirrhosis, active tuberculosis and AIDS.",{"count":51,"type":20},392,[53],"NA","Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the \"Yueya\" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.\n\nPatients will be divided into a group receiving support via the \"Yueya\" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.",[56,57],"End Stage Renal Disease (ESRD)","Maintenance Hemodialysis","2025-12-05",{"date":60,"type":35},"2025-12-18",{"date":62,"type":35},"2025-09-22",{"date":39,"type":20},{"name":41,"class":42},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":43},"100559799","the-effect-of-active-exercise-on-maintenance-haemodialysis-patients-100559799","NCT06568835","The Effect of Active Exercise on Maintenance Haemodialysis Patients","Effect of Active Exercise on Nutritional and Inflammatory Status, Muscle Metabolism and Cardiovascular Events in Maintenance Haemodialysis Patients","Inclusion Criteria:\n\n* MHD more than 3 months, 3 times per week, 3-4h each time;\n* Urea clearance index (Kt\u002FV) \\>1.2;\n* Stable condition, no serious infection, tumour and cardiovascular disease;\n* Willing to join the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Combined with serious heart and lung disease: such as repeated heart failure, severe arrhythmia, unstable angina pectoris, severe pericardial effusion, severe heart valve disease, hypertrophic cardiomyopathy, aortic coarctation, severe emphysema, pulmonary heart disease, severe pulmonary hypertension (average pressure of the pulmonary artery \\> 55mmHg), etc.;\n* Combined with chronic joints, muscles, or vascular disease can not be or is not suitable for regular exercise, such as cerebrovascular disease; combined chronic joint, muscle or vascular disease can not or are not suitable for regular exercise, such as cerebrovascular disease sequelae, serious lower limb joint damage, severe myopathy, deep vein thrombosis, etc.;\n* unwilling to cooperate with the movement of people",{"count":73,"type":20},200,[53],"The goal of this clinical trial is to discuss the effects of physical activity on nutrition, inflammation, muscle metabolism, and the occurrence of cardiovascular and cerebrovascular events in patients with maintenance haemodialysis. The main question it aims to answer is: can exercise improve nutritional and inflammatory status, enhance muscle strength, and reduce the incidence of cardiovascular and cerebrovascular events in patients with maintenance haemodialysis.\n\nResearchers will compared active exercise group to conventional treatment group to see the impact of exercise on maintenance haemodialysis patients.\n\nParticipants will:\n\nChoose low-intensity aerobic exercise workouts such as walking (no less than 8,000 steps per day) or jogging, swimming, Tai Chi, etc., according to their individual conditions, for no less than 30 minutes at a time, at least 3 times per week, and the intensity of the exercise should be based on an RPE score of 12 to 16.",[77],"Renal Dialysis",[79,80,81,82],"Exercise","Inflammation","Nutrition","Muscular Atrophy","2024-08-21",{"date":85,"type":35},"2024-08-23",{"date":87,"type":35},"2024-01-01",{"date":89,"type":20},"2025-07-01",{"name":41,"class":42},""]